Skip to main content

Hyderabad, India: Wednesday, 18th December, 2019.

Excelra (, a leading global Data and Analytics company, today announced a Drug Repurposing partnership with Keio University School of Medicine – a top research university in Japan to explore new therapeutics for a rare indication.

Under the agreement, a team of chemo-informaticians and data scientists at Excelra will collaborate with Dr. Toshiki Takenouchi, Assistant Professor of Paediatrics, to identify drugs with activity against a key target in the Takenouchi-Kosaki syndrome. The Takenouchi-Kosaki syndrome is a highly heterogenous autosomal complex congenital developmental disorder affecting multiple organ systems. Excelra’s scientists will leverage its proprietary Global Integrated Drug Repurposing Platform, comprising comprehensive repurposing databases, repurposing algorithms, analytics tools and visualization engines to expand the utility of approved drugs. The database within the Drug Repurposing Platform has been built by amassing chemical data (over 7 million chemical entities), biological data and clinical data (over 200,000 data points), together contributing to more than 10 million associations among ‘drug-disease-target’ triads.

Dr. Nandu Gattu, Senior Vice President, Pharma Analytics, Excelra said, “Drug Repurposing is an attractive strategy to reduce the cost of developing new therapies by tapping into the repertoire of approved drugs with a known safety profile. It is our privilege to work with Dr. Takenouchi in this endeavour to explore the therapeutic potential of existing drugs for a rare disease.”

About Excelra
Excelra’s data and analytics solutions empower innovation in life sciences across the value chain from discovery to market. The Excelra Edge comes from a seamless amalgamation of proprietary curated data assets, deep domain expertise and data science. The company’s multifaceted teams harmonize and analyse large volumes of disparate unstructured data using cutting-edge technologies; and galvanize data-driven decisions to unlock operational efficiencies to accelerate drug discovery and development. Over the past 18 years, Excelra has been the preferred data and analytics partner to over 150 global clients including 15 of the top 20 large Pharma.

Please fill the form

"*" indicates required fields

This will close in 0 seconds